跳到正文
原文
Medical Xpress·· 28 天前AI 评分38

利用癌细胞内源性一氧化碳实现癌症选择性药物合成的概念验证研究

Cancer cells' own carbon monoxide fuels anticancer drug production in lab tests

AI 导读

RIKEN PRI团队在Nature Communications发表概念验证研究,证实可利用癌细胞内过量的一氧化碳在细胞内原位合成抗癌药物。实验中白蛋白-钯环复合物保护钯催化剂免受谷胱甘肽破坏,在48小时内仅在人肝癌、宫颈癌、乳腺癌或肺癌细胞系中检测到酚嗪酮类毒性产物,正常细胞及血液中未生成该药物。研究团队表示下一步将从细胞系推进至动物模型。

正文
Cancer cells killed with their own carbon monoxide
Artistic rendering of the study's achievement: cancer-killing drug formation using excess carbon monoxide found inside cancer cells. Credit: RIKEN

What if we could use a cancer's own byproduct to make drugs that destroy tumor cells from the inside? That is what Katsunori Tanaka and his team have done at the RIKEN Pioneering Research Institute (PRI) in Japan.

Published in Nature Communications, the proof-of-concept study describes how a synthetically designed compound uses the excess carbon monoxide produced in tumor cells to trigger the production of anticancer drugs within the cells themselves. Treatment methods based on this technique would be ideal as they selectively target tumors and avoid harming healthy cells.

The concept

For cancer treatment to be the most effective, it must kill the cancer without producing harmful side effects. For traditional chemotherapies, the side effects may end up being just as harmful as the cancer. Tanaka and like-minded researchers are trying to improve treatments by devising new technologies that selectively target tumors.

At RIKEN, rather than injecting the body with cancer-killing drugs, Tanaka's goal is to eventually inject patients with harmless compounds that can be used to make drugs on the fly after they are picked up by cancer cells.

Most of us know about carbon monoxide, a poisonous gas commonly produced by the burning of gasoline in car engines. Recently, research has shown that many types of cancer cells also produce this gas. This makes carbon monoxide a kind of cancer biomarker, but only if it can be detected.

In the newly published experiments, scientists in the Biofunctional Synthetic Chemistry Laboratory at RIKEN PRI tested a system for bringing a metal catalyst into cells and then using it and excess carbon monoxide to make a toxic bioactive compound. Because cancer cells have excess carbon monoxide and healthy cells do not, only the cancer cells are exposed to the cytotoxic drug.

Cancer cells killed with their own carbon monoxide
This study's major achievement. After sending the albumin-palladocycle complex into cancer cells, the albumin was able to protect the palladium catalyst from glutathione. This allowed the catalyst to remain viable, and excess carbon monoxide within cancer cells could then be used to produce the drug, which was then freed up to kill the cancer cells. Credit: RIKEN

Designing the drug delivery system

The team focused on carbon monoxide because it can be used by organometallic complexes called palladacycles to make the organic compound phenanthridinone.

Several phenanthridinone derivatives are cytotoxic, meaning they kill cells, and have already been used in anticancer drugs. But simply putting palladacycles inside a tumor cell does nothing because the metal catalyst in the center is quickly destroyed by special molecules inside cells, such as glutathione.

To overcome this problem, Tanaka turned to his lab's unique specialty: in vivo metal-catalyzed reactions. Building off their previous studies, they placed a palladacycle inside albumin, a common protein found in the blood. The albumin–palladacycle complex can thus safely travel in the blood, and when it enters cells, the metal palladium catalyst is protected.

The proof of concept

The researchers tested this system at many stages. First, they screened a collection of palladacycles to find the one that yielded the most phenanthridinone. Next, they incubated the albumin–palladacycle complex for 48 hours with human liver, cervix, breast or lung cancer cell lines, as well as with a noncancerous cell line. After the 48 hours, they detected the desired product in the cancer lines, but not in the normal cells.

This showed both that the complex protected the catalyst from glutathione and that targeting was successful—the reaction only occurred in the cancer cells. A few adjustments ensured that the product would detach from the complex and freely move about the cell.

Once this was confirmed, they tweaked the albumin–palladacycle complex so that the reaction produced a specific kind of phenanthridinone that is highly toxic and used in anticancer drugs. When they tested it in the liver cancer cell line, they observed the drug being produced inside the cells, which subsequently suffered from the toxic drug's effects.

Carbon monoxide in blood was a potential concern as accidentally triggering production of the toxic drug in blood during transport would kill the blood cells before it arrived at the target location. However, when tested, blood remained free of the drug, presumably because carbon monoxide in blood is bound to hemoglobin, making it unavailable for the reaction.

"This work represents an important advance in therapeutic in vivo synthetic chemistry," says Tanaka. "In our therapeutic strategy, molecules naturally present or generated within the body—including disease-associated metabolites—are used as endogenous chemical feedstocks to synthesize therapeutic molecules directly at the site of disease."

The next step is to move from cultured cell lines to animal models.

Publication details

Masayuki Kawai et al., Harnessing endogenous carbon monoxide for cancer-selective drug synthesis, Nature Communications (2026). DOI: 10.1038/s41467-026-77616-8

Journal information: Nature Communications

Key medical concepts

Carbon Monoxide

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Cancer cells' own carbon monoxide fuels anticancer drug production in lab tests (2026, October 23) retrieved 23 October 2026 from https://medicalxpress.com/news/2026-10-cancer-cells-carbon-monoxide-fuels.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com